By Michael Gwarisa Doctors Without Borders/Médecins Sans Frontières (MSF) says limited access to to new drug delamanid reduces promising treatment options available for those with drug-resistant tuberculosis. According to MSF, almost three quarters (74%) of patients receiving a combination of these drugs for six months achieved ‘culture conversion’, an early indicator that treatment might ultimately be successful. “The WHO endorses delamanid to replace the injectable agent for children and adolescents with DR-TB in cases of intolerance or resistance to some drugs, giving this group an option that is more effective and…
Read MoreDrug Resistant TB Treatment Efforts Under Threat says MSF
